

**STEPHEN MINTON, MD
RR3 BOX C-9, SUNDANCE
PROVO, UT 84604**

November 19, 2013

Hope 4 Children with Epilepsy
P. O. Box 286
Pleasant Grove UT 84062

Dear Sirs:

I am writing in support of approval of the recently available Alepsia as a treatment option for children who have severe forms of epilepsy who have not been controlled by current medications. I am currently the Chief of Neonatology and Medical Director for Women and Newborn Services for the Urban South Region of Intermountain Healthcare. I am also a clinical attending in the NICU at Utah Valley Regional Medical Center.

Alepsia is made from an industrial hemp-quality hybrid cannabis plant and processed into an oil, tincture, or capsule. This cannabis is a new hybrid strain that is very high in medicinal CBD and only contains trace amounts of the psychoactive component THC. It does not cause a high.

The research on CBD has shown good anti-seizure properties, fewer side effects than the current anti-seizure medications, and a significant neuro-protective property.

Approval of Alepsia is a medical and public policy issue. It is not a drug with abuse potential.

These children with severe epilepsy have a decreased quality of life and are restricted in their ability to function. They deserve all the help they can get to control their seizures.

I strongly recommend your attention and support to this matter that is so critical to some of our children.

Yours truly,

A handwritten signature in black ink that reads "Stephen Minton, M.D." The signature is written in a cursive, flowing style.

Stephen Minton, MD
Chief of Neonatology
Medical Director Women and Newborn Services
Urban South Region
Intermountain Healthcare